Phaseline

Targets › APOL1

APOL1 (Apolipoprotein L1): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 2; Genitourinary; next expected readout Oct 2027.

May play a role in lipid exchange and transport throughout the body. May participate in reverse cholesterol transport from peripheral cells to the liver. (UniProt, O14791)

Open in Phaseline: the race on APOL1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AstraZenecaAZD2373
APOL1-mediated kidney disease inhibitor
APOL1Phase 2APOL1-Mediated Kidney DiseaseOct 2027
Vertex PharmaceuticalsVX-147
APOL1 inhibitor
APOL1Phase 2Proteinuric Kidney DiseaseJun 2028

Conditions

APOL1-Mediated Kidney Disease (1) Proteinuric Kidney Disease (1)

Modalities

small molecule (2)

Companies

AstraZeneca (1) Vertex Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.